Medtronic’s AdaptivCRT effectiveness in heart patients reinforced in new study

Medtronic's AdaptiveCRT treatment has been identified as an effective way of reducing atrial fibrillation (AF) episodes in patients with heart failure.

Two real-world analyses presented at the European Heart Rhythm Association (EHRA) Scientific Sessions 2018 in Barcelona, Spain, found that the treatment significantly reduces the incidence of AF episodes, while it was also associated with a higher daily activity level, when compared with those using conventional CRT.

Professor Alessandro Proclemer, from the University Hospital Santa Maria della Misericordia, Udine, Italy, described AF as a "common comorbidity" among patients with heart failure.

"Progression of AF is linked to an increased risk of stroke and death, so it is encouraging to see additional clinical data that again links AdaptivCRT with a reduction in the incidence of AF in these patients," he commented.

Dr Saverio Iacopino, from Maria Cecilia Hospital in Cotignola, Italy, added that the findings are important as heart failure patients with low activity levels are more likely to be hospitalised or even die.

"We want our patients to be as active as possible, given the seriousness of their heart condition," he said.

With over 20 years of experience within the medical devices market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current medical device roles we have available, you can search for the latest job roles, register your details, or contact the team today.